Cancer antigen 125 associated with multiple benign and malignant pathologies

Area of Science:

• Clinical Chemistry
• Oncology
• Internal Medicine

Background:

• Cancer antigen (CA) 125 is a glycoprotein utilized in epithelial ovarian cancer monitoring.
• CA 125 assays are frequently requested for differential diagnosis in cases of pleural or peritoneal fluid.
• This study investigates the prevalence and clinical significance of elevated CA 125 in a general hospital population.

Purpose of the Study:

• To determine the frequency of elevated CA 125 levels in a general hospital setting.
• To identify the range of pathologies associated with increased CA 125.
• To discuss the clinical utility of CA 125 beyond malignancy.

Main Methods:

• 380 CA 125 assays were conducted on randomly selected patients over four days.
• Serum CA 125 was quantified using a commercial enzyme immunoassay.
• Patient clinical records were retrospectively reviewed to correlate CA 125 levels with diagnoses.

Main Results:

• 16% of patients (61/380) exhibited elevated CA 125 levels.
• The most common associated pathologies included previous surgery (27.8%), lung disease (18%), and heart failure (14.7%).
• Malignant tumors accounted for 14.7% of elevated CA 125 cases, with effusions present in 55.7% of patients with high CA 125.

Conclusions:

• Elevated CA 125 is associated with a diverse spectrum of benign and malignant conditions.
• Cardiovascular and chronic liver diseases were frequent findings in patients with elevated CA 125, questioning its specificity for malignancy.
• CA 125 may possess value in monitoring cardiovascular, hepatic, and neoplastic diseases involving serosal surfaces.